Patents by Inventor Nicholas Kindon

Nicholas Kindon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8476265
    Abstract: Spirocyclic amide derivatives of formula I wherein ArCH2CH2NH— represents a ?-adrenoceptor binding group, processes for their preparation, pharmaceutical compositions containing them, a process for preparing such pharmaceutical compositions, their use in therapy, and intermediates for use in their preparation.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 2, 2013
    Assignees: AstraZeneca AB, Pulmagen Therapeutics (Synergy) Limited
    Inventors: Lilian Alcaraz, Andrew Bailey, Nicholas Kindon
  • Patent number: 8455483
    Abstract: Spirocyclic amide derivatives of formula I wherein ArCH2CH2NH— represents a ?-adrenoceptor binding group, processes for their preparation, pharmaceutical compositions containing them, a process for preparing such pharmaceutical compositions, their use in therapy, and intermediates for use in their preparation.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: June 4, 2013
    Assignees: AstraZeneca AB, Pulmagen Therapeutics (Synergy) Limited
    Inventors: Lilian Alcaraz, Andrew Bailey, Nicholas Kindon
  • Publication number: 20130018037
    Abstract: Spirocyclic amide derivatives of formula I wherein ArCH2CH2NH— represents a ?-adrenoceptor binding group, processes for their preparation, pharmaceutical compositions containing them, a process for preparing such pharmaceutical compositions, their use in therapy, and intermediates for use in their preparation.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Inventors: Lilian Alcaraz, Andrew Bailey, Nicholas Kindon
  • Publication number: 20110053909
    Abstract: Spirocyclic amide derivatives of formula I wherein ArCH2CH2NH— represents a ?-adrenoceptor binding group, processes for their preparation, pharmaceutical compositions containing them, a process for preparing such pharmaceutical compositions, their use in therapy, and intermediates for use in their preparation.
    Type: Application
    Filed: July 30, 2010
    Publication date: March 3, 2011
    Inventors: Lilian Alcaraz, Andrew Bailey, Nicholas Kindon
  • Publication number: 20100144759
    Abstract: The invention provides N-(fluoro-pyrazinyl)-phenylsulfonamides of formula (I) wherein R1-R5 are as defined in the specification; processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy
    Type: Application
    Filed: December 8, 2009
    Publication date: June 10, 2010
    Applicant: AstraZeneca AB
    Inventors: David CHESHIRE, Nicholas Kindon, Antonio Mete, Bryan Roberts
  • Publication number: 20100081670
    Abstract: The invention provides N-pyrazinyl-phenyl-sulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma.
    Type: Application
    Filed: May 5, 2009
    Publication date: April 1, 2010
    Inventors: Andrew Baxter, Timothy Johnson, Nicholas Kindon, Bryan Roberts, Michael Stocks
  • Patent number: 7662825
    Abstract: The invention provides N-pyrazinyl-phenyl-sulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: February 16, 2010
    Assignee: AstraZeneca AB
    Inventors: Andrew Baxter, Timothy Johnson, Nicholas Kindon, Bryan Roberts, Michael Stocks
  • Publication number: 20080293742
    Abstract: The invention provides N-(fluoro-pyrazinyl)-phenylsulfonamides of formula (I) wherein R1-R5 are as defined in the specification; processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy
    Type: Application
    Filed: December 11, 2006
    Publication date: November 27, 2008
    Inventors: David Cheshire, Nicholas Kindon, Antonio Mete, Bryan Roberts
  • Patent number: 7410972
    Abstract: The invention provides N-pyrazinyl-thienylsulphonamides of formula (I) for use in the treatment of chemokine mediated diseases.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: August 12, 2008
    Assignee: AstraZeneca AB
    Inventors: Andrew Baxter, Timothy Johnson, Nicholas Kindon, Bryan Roberts, John Steele, Michael Stocks, Nicholas Tomkinson
  • Publication number: 20070093491
    Abstract: The invention provides novel condensed N-pyrazinyl-sulphonamides of formula (I) and their use in the treatment of chemokine mediated diseases.
    Type: Application
    Filed: August 25, 2004
    Publication date: April 26, 2007
    Inventors: Andrew Baxter, Nicholas Kindon, Michael Stocks
  • Publication number: 20060025423
    Abstract: The invention provides N-pyrazinyl-phenyl-sulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma.
    Type: Application
    Filed: January 14, 2003
    Publication date: February 2, 2006
    Inventors: Andrew Baxter, Timothy Johnson, Nicholas Kindon, Bryan Roberts, Michael Stocks
  • Patent number: 6946478
    Abstract: The invention provides compounds of general formula wherein R1, m, Q, T, n, R2, R3, V, W, X and R4 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: January 9, 2003
    Date of Patent: September 20, 2005
    Assignee: AstraZeneca AB
    Inventors: Andrew Baxter, Stephen Brough, Nicholas Kindon, Thomas McInally, Bryan Roberts, Stephen Thom
  • Publication number: 20050075346
    Abstract: The invention provides N-pyrazinyl-thienylsulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma.
    Type: Application
    Filed: December 17, 2002
    Publication date: April 7, 2005
    Inventors: Andrew Baxter, Timothy Johnson, Nicholas Kindon, Bryan Roberts, John Steele, Michael Stocks, Nicholas Tomkinson
  • Patent number: 6812226
    Abstract: The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R1 and R2 are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their preparation.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: November 2, 2004
    Assignee: AstraZeneca AB
    Inventors: Andrew Baxter, Nicholas Kindon, Garry Pairaudeau, Bryan Roberts, Stephen Thom
  • Publication number: 20030134840
    Abstract: The invention provides compounds of general formula 1
    Type: Application
    Filed: January 9, 2003
    Publication date: July 17, 2003
    Applicant: AstraZeneca AB, a Sweden corporation
    Inventors: Andrew Baxter, Stephen Brough, Nicholas Kindon, Thomas Mclnally, Bryan Roberts, Stephen Thom
  • Publication number: 20030040513
    Abstract: The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R1 and R2 are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their preparation.
    Type: Application
    Filed: June 13, 2002
    Publication date: February 27, 2003
    Inventors: Andrew Baxter, Nicholas Kindon, Garry Pairaudeau, Bryan Roberts, Stephen Thom
  • Patent number: 6518286
    Abstract: The invention provides compounds of general formula (I) wherein: R1 represents optionally substituted, C1-C12 alkyl or optionally substituted 3- to 10-membered saturated or unsaturated ring system comprising up to two ring carbon atoms that form carbonyl groups and comprising up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur; m is 0-1; Q represents OCH2, C1-C4 alkylene or C2-C4 alkenylene; T represents C(O)NH, or when m is 0, T may additionally represent a bond or NH, or when m is 1 and Q represents C1-C4 alkylene, T may additionally represent NH; n is 1-4; each R2 and R3 independently represents H or C1-C4 alkyl; V represents N, and W represents N or CH; X represents O, C(O), CH(OH), SO2, NH or N(C1-C6 alkyl), provided that when W represents N, then X represents either C(O) or SO2 and when W represents CH, then X is other than SO2; R4 represents optionally substituted phenyl; R5 and R6 each independently represent H, C1-C6 alkyl or hydroxyC1-C6 alkyl, or R5 and R6 together with
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: February 11, 2003
    Assignee: AstraZeneca AB
    Inventors: Andrew Baxter, Stephen Brough, Nicholas Kindon, Thomas McInally, Bryan Roberts, Stephen Thom
  • Publication number: 20020086862
    Abstract: The invention provides certain 1,2,4-triazole-3-thione compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 10, 2001
    Publication date: July 4, 2002
    Applicant: AstraZeneca AB
    Inventors: Andrew Baxter, Colin Bennion, Peter Cage, Nicholas Kindon, Michael Mortimore, Bryan Roberts
  • Patent number: 6218376
    Abstract: Compounds of formula I or salts thereof where for example Y is a group of the formula (i) and R1 is a group of formula (ii) are provided along with compositions containing them and processes for their preparation. The compounds are P2-purinoreceptor 7-transmembrane G-protein coupled receptor antagonists, and are useful in the treatment of inflammatory conditions.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: April 17, 2001
    Assignee: AstraZeneca UK Limited
    Inventors: Nicholas Kindon, Premji Meghani, Stephen Thom
  • Patent number: 6200981
    Abstract: The invention relates to new pharmaceutically active compounds which are are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists, compositions containing them and processes for their preparation.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: March 13, 2001
    Assignee: AstraZeneca UK Limited
    Inventors: Nicholas Kindon, Premji Meghani, Stephen Thom